Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects

15:12 EDT 3 Jun 2018 | SCRIP

JAK inhibitor, now first oral UC medication in US, is approved for both 5mg and 10mg, but label currently discourages...

More From BioPortfolio on "Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects"